Spruce biosciences receives u.s. fda breakthrough therapy designation for tralesinidase alfa enzyme replacement therapy (ta-ert) in sanfilippo syndrome type b (mps iiib)

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that the u.s. food and drug administration (fda) has granted breakthrough therapy designation (btd) to tralesinidase alfa enzyme replacement therapy (ta-ert) for the treatment of sanfilippo syndrome type b (mps iiib). “we are pleased t.
SPRB Ratings Summary
SPRB Quant Ranking